Navigation Links
MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
Date:5/26/2009

- Both Rapid and Sustained Pain Relief for up to 48 Hours -

- Conference Call to be Held Today at 8:30 a.m. ET -

MOUNTAIN VIEW, Calif., May 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.

Patients taking LEVADEX therapy (formerly referred to as MAP0004) had statistically significant improvement at two hours compared to patients on placebo for each of the primary endpoints:

  • Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (p<0.0001);
  • Phonophobia free: 52.9 percent of patients who received LEVADEX compared with 33.8 percent for placebo (p<0.0001);
  • Photophobia free: 46.6 percent of patients who received LEVADEX compared with 27.2 percent for placebo (p<0.0001); and
  • Nausea free: 67.1 percent of patients who received LEVADEX compared with 58.7 percent for placebo (p=0.02).

A total of 792 patients were included in the primary data analysis as specified in the protocol of the FREEDOM-301 study, which was conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). The patient population studied had more severe migraine pain than expected, with 46 percent reporting severe pain and 54 percent reporting moderate pain prior to administration of the study drug.

Results from additional pre-defined analyses include:

  • LEVA
    '/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Agios Pharmaceuticals founders author Science review on cancer metabolism
2. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
3. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
4. Sagent Pharmaceuticals Announces Extension of Series A Financing
5. NSD Bio Group, LLC Selected By U.S. - China Economic & Security Review Commission for Analysis of Chinas Pharma Supply Chain on U.S. Pharmaceuticals
6. Aragon Pharmaceuticals Announces $8 Million Series A Financing
7. Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders
8. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
9. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
10. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
11. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 A new ... a 63% increase in disability associated with speech problems ... a more than 15% increase in disability associated with ... intervention for rising numbers of children who are experiencing ... (ASHA). , On a broader level, the ...
(Date:8/21/2014)... is to focus on her body in terms of ... her as a complete human being with thoughts and ... in the media, how does it affect individual romantic ... Quarterly , a SAGE journal, finds that more objectification ... incidents of sexual pressure and coercion., Researchers Laura R. ...
(Date:8/21/2014)... FRANCISCO Aug. 21, 2014 Researchers in the ... congenital cataracts can quickly and accurately diagnose a number ... a study published online today in ... Ophthalmology. Using a single test, doctors were able ... on their mutations reducing the time and money spent ...
(Date:8/21/2014)... 2014 Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) ... suffer uncontrollable internal bleeding and other serious injuries continue ... According to court documents, a wrongful death lawsuit was ... District of New York by the family of a ... that was allegedly caused by Xarelto. Among other thing, ...
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
Breaking Medicine News(10 mins):Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... WASHINGTON, July 22 The role of personal responsibility in ... Rethinking Responsibility: Reflections on Sex and Accountability. Released ... nonprofit, nonpartisan organization, the volume includes 29 essays written by leaders ... , Leading media voices, ...
... July 22 To help employers face the challenges of ... difficult economy, Sodexo, Inc., now offers a Quality of Life ... today the launch of the program designed to ... , , Sodexo, a ...
... , DALLAS, July 22 Texas ... Heart Association for providing quality, evidence-based care for coronary artery ... "This is another example of the dedication and commitment ... Dallas community by physicians, nursing, allied health professionals and administration," ...
... , WALNUT CREEK, Calif., July 22 ... cure with the recent approval by The National Institutes of Health ... scientists, parents and advocates. , , ... to highlight the work of the NIH,s Research Plan on Fragile ...
... demands of surgical careers, most surgeons would still choose their ... postpone having children or to not have children at all ... national survey conducted by UC Davis researchers has found. The ... Surgery , one of the JAMA/Archives journals. "Surgery is ...
... associated with varied, disproportionate, asymmetric overgrowth of many ... seen in Proteus syndrome is progressive and difficult ... treatment for the progressive overgrowth of tissue over ... functional and cosmetic consequences, so surgical intervention is ...
Cached Medicine News:Health News:National Leaders Examine Sex and Responsibility in New Book 2Health News:National Leaders Examine Sex and Responsibility in New Book 3Health News:Sodexo Offers Landmark Program to Promote Employee Health and Worklife Balance 2Health News:Texas Health Dallas Receives Double Honor From American Heart Association 2Health News:NIH Plan Charts Course to Better Treatments and Cure for Most Common Known Genetic Cause of Autism: Fragile X 2Health News:UC Davis study highlights work-life issues of female surgeons 2
(Date:8/21/2014)... 21, 2014   Memorial Hermann Health System and ... today announced a new partnership to provide a new level ... care centers in the greater Houston ... become the exclusive provider of professional breast radiology services for ... Memorial City, The Woodlands , Northeast, Southwest ...
(Date:8/21/2014)... Aug. 21, 2014  Publicis Groupe customer engagement ... Managing Partner and Healthcare Industry Group Leader, has been ... recognizes the most inspiring people in the life-sciences industry. ... research and development, marketing, technology, creativity, strategy and medicine. ... as a partner in its leading Rosetta Consulting practice. ...
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014  IBM (NYSE: ... Deutsches Elektronen-Synchrotron ( DESY ), a leading national research ... up management and storage of massive volumes of x-ray ... architecture based on IBM software defined technology can handle ... peak performance and help scientists worldwide gain faster insights ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Shannon Hartley Shines in PharmaVOICE 100 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... Tech acclaimed GT-CAPTURE digital camera photomicrographic system ... microscope such as Olympus, Leica, Nikon, and ... and transferring images over the Internet easy ... and a performance-proven Nikkor lens. The system ...
... superb stand-alone digital camera with networking capability ... or remote locations. Image acquisition and camera ... operates independently or attaches directly to a ... to capture and transfer images. Sharing images ...
... are a new generation of flexible CCD cameras, ... video imaging. Images are captured by a high-resolution ... and digital formats. Video signals include composite video, ... to the PC as uncompressed TIFF files. And ...
Console Horizontal Airflow Cabinet...
Medicine Products: